- The European Patent Office has upheld Biogen Inc.'s patent coveringthe recombinant production of hepatitis B virus antigens. The patentwas revoked in 1991 and the decision reinstating it is not subject toappeal, according to Cambridge, Mass.-based company.- Synbiotics Corp., of San Diego, said it owns a 5 percent interest inTexas Biotechnology as a result of the Houston-based company'sacquisition of Immuno-Pharmaceuticals Inc. Synbiotics owned 41percent of ImmunoPharmaceuticals at the time of the acquisition,receiving 654,982 shares of Texas Biotechnology and a possibility ofacquiring another 982,560 shares based on future milestone payments.Synbiotics said it intends to hold its shares of Texas Biotechnology asan investment.

(c) 1997 American Health Consultants. All rights reserved.